<div id="readability-page-1"><p>Atlas Capital Advisors Inc. raised its stake in  CVS Health Corporation (NYSE:CVS - Free Report) by 1,463.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor  owned 16,898 shares of the pharmacy operator's stock after purchasing an additional 15,817 shares during the period. Atlas Capital Advisors Inc.'s holdings in CVS Health were worth $1,145,000 as of its most recent filing with the Securities and Exchange Commission (SEC).</p><ul><li>MarketBeat Week in Review – 05/12 - 05/16</li></ul><p>A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of  CVS Health by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 118,335,394 shares of the pharmacy operator's stock worth $8,017,223,000 after acquiring an additional 969,027 shares in the last quarter.  Dodge &amp; Cox raised its position in shares of  CVS Health by 11.2% during the 4th quarter. Dodge &amp; Cox now owns 70,105,899 shares of the pharmacy operator's stock worth $3,147,054,000 after acquiring an additional 7,075,209 shares in the last quarter.  Capital World Investors raised its position in shares of  CVS Health by 26.6% during the 4th quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock worth $2,739,927,000 after acquiring an additional 12,819,148 shares in the last quarter.  Capital International Investors raised its position in shares of  CVS Health by 4.8% during the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock worth $1,196,989,000 after acquiring an additional 1,212,126 shares in the last quarter.  Finally, Charles Schwab Investment Management Inc. grew its stake in  CVS Health by 5.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 13,647,873 shares of the pharmacy operator's stock worth $924,643,000 after buying an additional 728,924 shares during the last quarter. Institutional investors and hedge funds own  80.66% of the company's stock. </p><h2>Insider Transactions at CVS Health</h2><p>In related news, Director Guy P. Sansone purchased 1,570 shares of the business's stock in a transaction dated Thursday, June 5th. The stock was bought at an average cost of $63.70 per share, with a total value of $100,009.00. Following the completion of the acquisition, the director directly owned 12,007 shares in the company, valued at $764,845.90. The trade was a 15.04% increase in their position. The acquisition was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Corporate insiders own  1.22% of the company's stock. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Is It Time to Buy the Dip in Novo Nordisk Stock?</li></ul><p>A number of research firms recently issued reports on CVS. Barclays raised their price target on CVS Health from $79.00 to $80.00 and gave the stock an &#34;overweight&#34; rating in a research note on Friday, August 1st. Bernstein Bank dropped their price target on CVS Health from $78.00 to $72.00 and set a &#34;market perform&#34; rating on the stock in a research note on Wednesday, July 16th. Jefferies Financial Group raised their price target on CVS Health from $74.00 to $80.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, June 30th. Royal Bank Of Canada raised their price target on CVS Health from $74.00 to $81.00 and gave the stock an &#34;outperform&#34; rating in a research note on Monday, May 5th. Finally, Wells Fargo &amp; Company  restated an &#34;overweight&#34; rating and set a $84.00 price target (up previously from $76.00) on shares of CVS Health in a research note on Tuesday, May 6th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued  a buy rating and one  has issued  a strong buy rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $75.11.</p><p><b>Check Out Our Latest Research Report on CVS Health</b></p><h2>CVS Health Stock Performance</h2><ul><li>Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?</li></ul><p>Shares of CVS stock opened at $65.49 on Friday. The stock has a fifty day moving average price of $64.68 and a 200 day moving average price of $64.23. The stock has a market cap of $83.06 billion, a PE ratio of 18.29, a P/E/G ratio of 0.70 and a beta of 0.58. CVS Health Corporation has a 1 year low of $43.56 and a 1 year high of $72.51. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. </p><p>CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The pharmacy operator reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.35. The firm had revenue of $98.92 billion during the quarter, compared to analysts' expectations of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%. CVS Health's revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.83 earnings per share.  Sell-side analysts forecast that  CVS Health Corporation will post 5.89 earnings per share for the current fiscal year. </p><h2>CVS Health Dividend Announcement</h2><p>The company also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Tuesday, July 22nd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Tuesday, July 22nd. This represents a $2.66 annualized dividend and a yield of 4.1%. CVS Health's payout ratio is currently 74.30%. </p><h2>CVS Health Profile</h2> (Free Report)<p>CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy &amp; Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than CVS Health</li><li>P/E Ratio Calculation: How to Assess Stocks</li><li>MarketBeat Week in Review – 08/04 - 08/08</li><li>Business Services Stocks Investing</li><li>Airbnb Beats Earnings, But the Growth Story Is Losing Altitude</li><li>What Are the FAANG Stocks and Are They Good Investments?</li><li>Netflix Bulls vs. Bears: Who Wins This Pullback?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNWUw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in CVS Health Right Now?</h2><p>Before you consider CVS Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.</p><p>While CVS Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Atlas Capital Advisors Inc. significantly increased its stake in CVS Health Corporation by 1,463.2% in Q1, now owning 16,898 shares valued at $1,145,000. Other institutional investors, including Vanguard and Dodge & Cox, also raised their positions. CVS Health's stock has a consensus rating of "Moderate Buy" with a price target of $75.11. The stock opened at $65.49, with a market cap of $83.06 billion and a PE ratio of 18.29. CVS Health's shares have fluctuated between a low of $43.56 and a high of $72.51 over the past year.</p>

CVS Health Corporation (NYSE:CVS) Shares Bought by Atlas Capital Advisors Inc.